Chance Pharma Partners with Huadong Medicine to Launch CXG87 for Respiratory Health

Introduction

In a significant move for the biotechnology sector, Chance Pharmaceuticals, a clinical-stage biotech innovator, has announced an exclusive commercialization agreement with Huadong Medicine, a prominent pharmaceutical company based in Hangzhou, China. This partnership focuses on the innovative respiratory medication CXG87, designed to offer improved management for patients suffering from respiratory diseases, particularly asthma.

About the Agreement

The agreement stipulates that Chance Pharma, as the Marketing Authorization Holder (MAH), will lead the drug's research and development, registration, manufacturing, and supply chain operations. In return, Chance will earn an upfront fee along with regulatory and commercial milestones and a percentage of the sales profits. Meanwhile, Huadong Medicine will take on the responsibility for the marketing and commercialization of CXG87 within Mainland China, leveraging its extensive distribution networks.

The Innovation Behind CXG87

CXG87 is an advanced formulation of budesonide/formoterol, classified as a Class 2.2 new drug. It presents significant improvements over the existing treatments available, such as having a lower dependency on flow rates, which makes it particularly beneficial for patients with compromised inspiratory flow. This innovation aims to enhance usability and ensure a more consistent therapeutic effect for users.

Currently, CXG87 has completed enrollment for its Phase III clinical trials, which focus on its efficacy in treating asthma. The application for new drug approval is anticipated to be submitted in the first half of 2026, showcasing Chance Pharma's commitment to bringing this promising product to market swiftly.

Leadership Insights

Liang Lv, Chairman and General Manager of Huadong Medicine, expressed optimism about CXG87’s potential in enhancing their respiratory medicine portfolio. With the integration of their national marketing framework and specialized promotion teams, he believes that they can achieve rapid market access, ensuring CXG87 reaches patients who need it most as quickly as possible.

On the other side, Dr. Donghao Chen, Founder and CEO of Chance Pharma, highlighted that CXG87 represents the first product developed using their proprietary VFC platform, which underscores its unique scientific and commercial merits. Dr. Chen shared his excitement about the collaboration with Huadong, seeing it as a means to maximize CXG87’s clinical and commercial potential through shared expertise.

Dr. Lan Chen, the Co-founder and Head of Research and Development at Chance Pharma, also emphasized the enhancements made to CXG87 compared to the traditional Symbicort® Turbuhaler®. The improvements stem from targeted preclinical and clinical studies aimed at showcasing the drug's clinical advantages.

About Chance Pharmaceuticals

Founded in 2015, Chance Pharmaceuticals has made a name for itself as a leading figure in the clinical research arena, especially concerning innovative dry powder inhalation therapies. Their two principal technology platforms—milling/blending and spray drying—enable the creation of highly efficient inhalation formulations. Their comprehensive development and manufacturing facility adheres to international standards, further elevating their capabilities in turning innovative concepts into effective treatments.

About Huadong Medicine

Huadong Medicine, established in 1993, has grown into a significant player in the pharmaceutical industry with four core divisions centered around manufacturing, commerce, medical aesthetics, and industrial microbiology. The company's combined experience and extensive infrastructure position it well in the competitive pharmaceutical landscape.

Conclusion

The partnership between Chance Pharmaceuticals and Huadong Medicine not only signifies an important milestone for the development and commercialization of CXG87 but also reflects a broader trend of collaboration among biotech firms and large pharmaceutical companies in the effort to bring innovative treatments to market. As we continue to observe the evolution of respiratory therapies, the success of CXG87 could mark a turning point in how respiratory diseases are managed in China and beyond.